Hermann Einsele

73.6k total citations · 11 hit papers
761 papers, 29.8k citations indexed

About

Hermann Einsele is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Hermann Einsele has authored 761 papers receiving a total of 29.8k indexed citations (citations by other indexed papers that have themselves been cited), including 342 papers in Hematology, 324 papers in Oncology and 216 papers in Molecular Biology. Recurrent topics in Hermann Einsele's work include Multiple Myeloma Research and Treatments (247 papers), CAR-T cell therapy research (124 papers) and Antifungal resistance and susceptibility (108 papers). Hermann Einsele is often cited by papers focused on Multiple Myeloma Research and Treatments (247 papers), CAR-T cell therapy research (124 papers) and Antifungal resistance and susceptibility (108 papers). Hermann Einsele collaborates with scholars based in Germany, United States and France. Hermann Einsele's co-authors include Holger Hebart, Juergen Loeffler, Ulrike Schumacher, Jürgen Löffler, Michael Hudecek, Michael Boeckh, Per Ljungman, Jan Storek, Stefan Knop and Ralf C. Bargou and has published in prestigious journals such as Science, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Hermann Einsele

729 papers receiving 29.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

2009 1.1k citations Hermann Einsele et al. profile →
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008 798 citations Stefan Knop, Hermann Einsele et al. profile →
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Bernd Metzner, Hermann Einsele et al. Blood profile →
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

2006 535 citations Hermann Einsele et al. Journal of Clinical Oncology profile →
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Pieter Sonneveld et al. profile →
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

2014 488 citations Max S. Topp, Hermann Einsele et al. Journal of Clinical Oncology profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

2019 379 citations Hermann Einsele et al. profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Johannes Duell, Philippe Moreau et al. Journal of Clinical Oncology profile →
Therapeutic advances of targeting receptor tyrosine kinases in cancer

2024 80 citations Ciprian Tomuleasa, Adrian Bogdan Țigu et al. Signal Transduction and Targeted Therapy profile →
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

2023 77 citations Noopur Raje, Kenneth C. Anderson et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Hermann Einsele

Since Specialization

Citations

This map shows the geographic impact of Hermann Einsele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hermann Einsele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hermann Einsele more than expected).

Fields of papers citing papers by Hermann Einsele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hermann Einsele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hermann Einsele. The network helps show where Hermann Einsele may publish in the future.

Co-authorship network of co-authors of Hermann Einsele

This figure shows the co-authorship network connecting the top 25 collaborators of Hermann Einsele. A scholar is included among the top collaborators of Hermann Einsele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hermann Einsele. Hermann Einsele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unveiling immune interference: how the dendritic cell response to co-infection with Aspergillus fumigatus is modulated by human cytomegalovirus and its virokine _CMV IL-10 2025 ·mBio ·(unknown), (unknown), (unknown), (unknown), Oliver Kurzai, Arnhild Grothey, Lars Dölken, Kerstin Laib Sampaio, Gianni Panagiotou, Alexander J. Westermann, Hermann Einsele, Sebastian Wurster, Sascha Schäuble, Juergen Loeffler	1
2	Needs of amyloidosis patients and their care providers: design & first results of the AMY-NEEDS research and care program 2024 ·Orphanet Journal of Rare Diseases ·(unknown), (unknown), (unknown), Stefan Frantz, Hermann Einsele, Stefan Störk, Silke Neuderth	2
3	Therapeutic advances of targeting receptor tyrosine kinases in cancer breakdown → 2024 ·Signal Transduction and Targeted Therapy ·Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, Cristian Moldovan, (unknown), Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce	80
4	Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement 2024 ·Blood ·(unknown), (unknown), Lisa Leypoldt, (unknown), Xiang Zhou, (unknown), (unknown), (unknown), (unknown), (unknown), Winfried Alsdorf, Max S. Topp, Johannes Duell, (unknown), Johannes M. Waldschmidt, Carsten Bokemeyer, Hermann Einsele, K. Martin Kortüm, Katja Weisel, Leo Rasche	0
5	Real-World Confirmatory Analysis of the Current IMWG Diagnostic Criteria Identifies Early Transformation As Major Risk Factor in Plasma Cell Leukemia 2024 ·Blood ·(unknown), Sophia Danhof, Xiang Zhou, (unknown), (unknown), (unknown), (unknown), Georg Fette, M. Anton Ertl, Hermann Einsele, (unknown), K. Martin Kortüm, Leo Rasche, Johannes M. Waldschmidt	0
6	Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. 2024 ·Journal of Clinical Oncology ·Bertrand Arnulf, Tessa Kerre, Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, Helen Varsos, (unknown), Jordan M. Schecter, Kevin C. De Braganca, Yogesh Jethava, Qingxuan Song, Mythili Koneru, Muhammad Akram, Yaël C. Cohen, Wilfried Roeloffzen	2
7	Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. 2024 ·Journal of Clinical Oncology ·Paula Rodríguez‐Otero, Philippe Moreau, Meletios Α. Dimopoulos, Meral Beksaç, Aurore Perrot, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Fredrik Schjesvold, Michel Delforge, Hermann Einsele, Andrew Spencer, Sarah Lonergan, Diego Vieyra, Anna Sitthi-Amorn, Robin Carson, Joan Bladé, Mario Boccadoro, Pieter Sonneveld	9
8	Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells 2023 ·Blood ·(unknown), (unknown), Cornelia Vogt, Larissa Haertle, (unknown), (unknown), (unknown), (unknown), Xiang Zhou, Santiago Barrio, Hermann Einsele, Johannes M. Waldschmidt, Leo Rasche, Markus Sauer, K. Martin Kortüm	2
9	Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel breakdown → 2023 ·Blood Cancer Journal ·Noopur Raje, Kenneth C. Anderson, Hermann Einsele, Yvonne A. Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina K. Patel, Karthik Ramasamy, María‐Victoria Mateos	77
10	Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy 2023 ·Blood ·Johannes Duell, Alexander M. Leipold, Silke Appenzeller, (unknown), Hilka Rauert‐Wunderlich, Matteo Da Vià, Oliver Dietrich, (unknown), Fabian Imdahl, Florian Eisele, (unknown), (unknown), Hermann Einsele, Niels Weinhold, Andreas Rosenwald, Max S. Topp, Antoine‐Emmanuel Saliba, Leo Rasche	25
11	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma 2021 ·Transplantation and Cellular Therapy ·Hermann Einsele, Niels W.C.J. van de Donk, Bertrand Arnulf, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, William Deraedt, Hong Tian, Martin Vogel, Marlene J. Carrasco-Alfonso, Muhammad Akram, (unknown), Tonia Nesheiwat, María‐Victoria Mateos, Saad Z. Usmani	0
12	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis 2021 ·Transplantation and Cellular Therapy ·Jesús G. Berdeja, Noopur Raje, David S. Siegel, Yi Lin, Larry D. Anderson, Paula Rodríguez‐Otero, Salomon Manier, Hermann Einsele, Michèle Cavo, Anna Truppel-Hartmann, Everton Rowe, (unknown), Julie Wang, Timothy Campbell, Sundar Jagannath	2
13	Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma 2021 ·European Journal Of Haematology ·Christian Straka, Hans Salwender, Stefan Knop, Martin Vogel, (unknown), Bernd Metzner, Christian Langer, Herbert G. Sayer, Wolfram Jung, Heinz Dürk, Florian Bassermann, Martin Gramatzki, Wolf Rösler, Hans‐Heinrich Wolf, Wolfram Brugger, Monika Engelhardt, Thomas Fischer, Peter Liebisch, Hermann Einsele	4
14	Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies 2020 ·Journal of Clinical Medicine ·Cătălin Constantinescu, Sergiu Paşca, Alina‐Andreea Zimța, (unknown), (unknown), Patric Teodorescu, (unknown), Alina Tănase, Anca Coliţă, Ólafur E. Sigurjónsson, Hermann Einsele, Ciprian Tomuleasa	1
15	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease 2017 ·Journal of Clinical Microbiology ·Jan Springer, P. Lewis White, Johanna Kessel, Imke Wieters, Daniel Teschner, (unknown), Tobias Liebregts, Oliver A. Cornely, Stefan Schwartz, Thomas Elgeti, Lisa Meintker, Stefan W. Krause, Raquel Posso, Werner Heinz, (unknown), Jörg Janne Vehreschild, Hermann Einsele, Volker Rickerts, Juergen Loeffler	30
16	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement 2016 ·Clinical Cancer Research ·Leo Rasche, Emmanuelle Ménoret, Valentina Dubljevic, Eline Menu, Karin Vanderkerken, Constantin Lapa, Torsten Steinbrunn, Manik Chatterjee, Stefan Knop, (unknown), Deanne L.V. Greenwood, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Stephanie Brändlein	47
17	‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factors 2015 ·European Journal Of Haematology ·Sophia Danhof, Martin Schreder, Leo Rasche, Susanne Strifler, Hermann Einsele, Stefan Knop	62
18	Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412 2011 ·Blood ·(unknown), (unknown), Elita Avota, (unknown), Manuela Battaglia, (unknown), Hermann Einsele, Thomas Hünig	106
19	In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment 2011 ·Arthritis & Rheumatism ·Petra Roll, Khalid Muhammad, (unknown), Stefan Kleinert, Hermann Einsele, Thomas Dörner, Hans‐Peter Tony	78
20	Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib 2008 ·Clinical Cancer Research ·(unknown), (unknown), Linda Wooldridge, Matthew Clement, Angharad E. Fenton-May, Andrew K. Sewell, (unknown), Elisabeth Greiner, Emma Gostick, David A. Price, Hermann Einsele, Ruth Seggewiss	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact